Key result
NKH477 reduces Ea/Emax by ~52%, improving A-V coupling more than dobutamine in LV systolic dysfunction.
Why the study?
Does NKH477 improve arterial-ventricular coupling and mechanical energy transduction compared to dobutamine in patients with left ventricular systolic dysfunction?
Does NKH477 improve arterial-ventricular coupling and mechanical energy transduction compared to dobutamine in patients with left ventricular systolic dysfunction?
NKH477 may be a superior alternative to dobutamine for improving arterial-ventricular coupling and mechanical energy transduction in patients with left ventricular systolic dysfunction.
Answers are grounded in this paper and cite their sources.
NKH477 may improve coupling efficiency more than dobutamine; hypothesis-generating in small Level 5 study, larger trials needed.
Summary: We examined the effects of a novel water-soluble forskolin derivative, NKH477 (0.5 μg/kg/min), on arterial-ventricular (A-V) coupling and mechanical energy transduction from heart to circulatory bed in comparison with those of dobutamine (3 μg/kg/min) in 8 patients with left ventricular (LV) systolic dysfunction using a conductance catheter method. A-V coupling was assessed as the ratio of the effective arterial elastance (Ea) to the slope of the end-systolic pressure-volume relation (ESPVR) (Emax, left ventricular contractility index), and the ratio of mechanical energy transduction was obtained as the fraction of PV area (PVA) comprised of stroke work (SW). Emax (2.59 mm Hg/ml/m2), Ea/Emax (1.62), and SW/PVA (0.58) were impaired in control contractile state. NKH477 increased Emax to the same extent as dobutamine. Ea decreased with NKH477 but not with dobutamine. As a consequence, the decrease in Ea/Emax with NKH477 was greater than that with dobutamine (52 vs. 47%, p < 0.05); the increase in SW/PVA with NKH477 was also greater than that with dobutamine (28 vs. 21%, p < 0.05). These findings suggest that NKH477 may be a superior alternative to dobutamine in A-V coupling and mechanical energy transduction in patients with LV systolic dysfunction.
No takes yet. Share an insight, caveat, or question.
Mori et al. (1994) studied Left ventricular systolic dysfunction (n=8). NKH477 vs. Dobutamine (3 μg/kg/min) was evaluated on Decrease in Ea/Emax (p=< 0.05). NKH477 produced a greater decrease in Ea/Emax and a greater increase in SW/PVA compared to dobutamine in patients with LV systolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: